Brief: Spruce Biosciences Provides Clinical Program Updates And Outlines Anticipated Milestones For 2023

Spruce Biosciences

09/01/2023 13:36

Jan 9 (Reuters) - Spruce Biosciences Inc  SPRB.O :
    * SPRUCE BIOSCIENCES PROVIDES CLINICAL PROGRAM UPDATES AND
OUTLINES ANTICIPATED MILESTONES FOR 2023
    * SPRUCE BIOSCIENCES INC - TOPLINE RESULTS FROM CAHMELIA-203
IN
ADULT CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) ANTICIPATED
IN 2H 2023
    * SPRUCE BIOSCIENCES INC - TOPLINE DATA IN PHASE 2
P.O.W.E.R.
STUDY IN POLYCYSTIC OVARY SYNDROME ANTICIPATED IN 1H 2023
    * SPRUCE BIOSCIENCES INC - ESTIMATES THAT ITS CASH, CASH
EQUIVALENTS, AND INVESTMENTS WERE ABOUT $79 MILLION AS OF
DECEMBER 31, 2022
    * SPRUCE BIOSCIENCES INC - CASH RUNWAY IS EXPECTED TO EXTEND
INTO
FIRST HALF OF 2024

Source text for Eikon:  ID:nBwb5NMcma 
Further company coverage:  SPRB.O 
 ((Reuters.Briefs@thomsonreuters.com;;))